Advertisement
ACB vs RGC
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Hold and RGC is a Hold.
ACB's RSI Oscillator peaks and leaves overbought zone
The 10-day RSI Indicator for ACB moved out of overbought territory on October 07, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 instances where the indicator moved out of the overbought zone. In 16 of the 18 cases the stock moved lower in the days that followed. This puts the odds of a move down at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for ACB turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 38 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
ACB broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on September 21, 2026. You may want to consider a long position or call options on ACB as a result. In 69 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The 50-day moving average for ACB moved above the 200-day moving average on September 30, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +17.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACB advanced for three days, in 175 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 97 of 116 cases where ACB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. ACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.695) is normal, around the industry mean (43.873). P/E Ratio (19.440) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.984) is also within normal values, averaging (178.797).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
RGC saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for RGC moved out of overbought territory on October 12, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 38 similar instances where the indicator exited the overbought zone. In 34 of the 38 cases the stock moved lower. This puts the odds of a downward move at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
RGC broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 23, 2026. You may want to consider a long position or call options on RGC as a result. In 77 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
RGC moved above its 50-day moving average on September 16, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +18.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGC advanced for three days, in 152 of 175 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Aroon Indicator entered an Uptrend today. In 125 of 149 cases where RGC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. RGC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RGC's P/B Ratio (2500.000) is very high in comparison to the industry average of (43.873). P/E Ratio (0.000) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
ACB | RGC | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 49 Fair valued | 94 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 100 | |
PRICE GROWTH RATING 1..100 | 40 | 35 | |
P/E GROWTH RATING 1..100 | 86 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ACB's Valuation (49) in the Pharmaceuticals Other industry is somewhat better than the same rating for RGC (94) in the Movies Or Entertainment industry. This means that ACB’s stock grew somewhat faster than RGC’s over the last 12 months.
ACB's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as RGC (100) in the Movies Or Entertainment industry. This means that ACB’s stock grew similarly to RGC’s over the last 12 months.
ACB's SMR Rating (96) in the Pharmaceuticals Other industry is in the same range as RGC (100) in the Movies Or Entertainment industry. This means that ACB’s stock grew similarly to RGC’s over the last 12 months.
RGC's Price Growth Rating (35) in the Movies Or Entertainment industry is in the same range as ACB (40) in the Pharmaceuticals Other industry. This means that RGC’s stock grew similarly to ACB’s over the last 12 months.
ACB's P/E Growth Rating (86) in the Pharmaceuticals Other industry is in the same range as RGC (100) in the Movies Or Entertainment industry. This means that ACB’s stock grew similarly to RGC’s over the last 12 months.
| ACB | RGC | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 89% | 3 days ago 81% |
| Stochastic ODDS (%) | 3 days ago 80% | 3 days ago 89% |
| Momentum ODDS (%) | 3 days ago 77% | 3 days ago 86% |
| MACD ODDS (%) | 3 days ago 84% | N/A |
| TrendWeek ODDS (%) | 3 days ago 87% | 3 days ago 81% |
| TrendMonth ODDS (%) | 3 days ago 78% | 3 days ago 83% |
| Advances ODDS (%) | 13 days ago 76% | 3 days ago 87% |
| Declines ODDS (%) | 3 days ago 84% | 7 days ago 89% |
| BollingerBands ODDS (%) | 3 days ago 85% | 3 days ago 86% |
| Aroon ODDS (%) | 3 days ago 84% | 3 days ago 84% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACB’s FA Score shows that 0 FA rating(s) are green while RGC’s FA Score has 0 green FA rating(s).
- ACB’s FA Score: 0 green, 5 red.
- RGC’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACB’s TA Score shows that 5 TA indicator(s) are bullish while RGC’s TA Score has 4 bullish TA indicator(s).
- ACB’s TA Score: 5 bullish, 4 bearish.
- RGC’s TA Score: 4 bullish, 4 bearish.
Price Growth
ACB (@Pharmaceuticals: Generic) experienced а -11.14% price change this week, while RGC (@Pharmaceuticals: Generic) price change was +30.48% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -6.95%. For the same industry, the average monthly price growth was -5.23%, and the average quarterly price growth was +10.96%.
Reported Earning Dates
ACB is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-6.95% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| XLRE | 42.16 | 0.17 | +0.40% |
| State Street Real Estate Select Sector SPDR ETF (XLRE) | |||
| SDFI | 34.90 | 0.02 | +0.06% |
| AB Short Duration Income ETF (SDFI) | |||
| TBLU | 50.21 | N/A | N/A |
| Tortoise Global Water ETF (TBLU) | |||
| WSML | 33.76 | -0.22 | -0.63% |
| iShares MSCI World Small-Cap ETF (WSML) | |||
| KTUP | 3.62 | -0.06 | -1.63% |
| T-REX 2X Long KTOS Daily Target ETF (KTUP) | |||
RGC and
Correlation & Price change
A.I.dvisor tells us that RGC and HIMS have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RGC and HIMS's prices will move in lockstep.
| Ticker / NAME | Correlation To RGC | 1D Price Change % | ||
|---|---|---|---|---|
| RGC | 100% | +0.74% | ||
| HIMS - RGC | 22% Poorly correlated | -4.46% | ||
| QNTM - RGC | 21% Poorly correlated | -8.86% | ||
| ACB - RGC | 21% Poorly correlated | -2.68% | ||
| SBFM - RGC | 20% Poorly correlated | -3.57% | ||
| KMDA - RGC | 20% Poorly correlated | -0.89% | ||
More | ||||